European Medicines Agency
European Medicines Agency (EMA) is a European Union agency responsible for the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or EMEA.
History
The EMA was established in 1995 with the aim to harmonize the supervision of medicinal products in the EU. It replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, although both of these committees still exist within the EMA structure.
Function
The EMA is responsible for the scientific evaluation of applications for European marketing authorisation for medicinal products (a process known as the 'centralised procedure'). Once granted by the European Commission, a centralised (or 'Community') marketing authorisation is valid in all EU Member States, the European Economic Area-EFTA states (Iceland, Liechtenstein and Norway) and the UK.
Structure
The EMA operates as a decentralised scientific agency (as opposed to a regulatory authority) of the EU and is governed by a Management Board. The Board is composed of representatives of EU Member States, the European Commission, the European Parliament, patient organizations, and healthcare professionals.
Location
The EMA was originally located in London, United Kingdom, but moved to Amsterdam, the Netherlands, in March 2019 due to the UK's decision to leave the EU (Brexit).
Criticism and Controversy
The EMA has faced criticism over its handling of safety issues with approved drugs, with some critics claiming that the agency is too quick to approve drugs and too slow to withdraw them once problems become apparent.
See also
- Pharmaceutical industry in the European Union
- Regulation of therapeutic goods
- Food and Drug Administration (US equivalent)
- European Centre for Disease Prevention and Control
- European Institute of Innovation and Technology
- European Food Safety Authority
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian

